- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks | ||
| Mi | AstraZeneca rare disease drug fails key trial tests | ||
| Mi | J&J absorbs Stelara, tariff hits to deliver beat-and-raise quarter | ||
| Mi | Moderna's latest approval again reveals FDA rift over COVID vaccines | ||
| Mi | 33 states pick up CMS program to pay for sickle cell gene therapies | ||
| Di | Cancer drugmaker LaNova to sell to China's Sino Biopharm | ||
| Di | Hengrui, Kailera say dual-acting obesity shot succeeds in China study | ||
| Di | Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug | ||
| Mo | AstraZeneca blood pressure drug succeeds in late-stage trial | ||
| Mo | Private equity firms back PCI Pharma in bet on drug production | ||
| Mo | FDA rejects Ultragenyx gene therapy over manufacturing concerns | ||
| Mo | Takeda to seek approval of new kind of narcolepsy drug after study data | ||
| Mo | From data to decisions: How pharma can move faster without sacrificing trust | ||
| Fr | Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update | ||
| Fr | With Verona Pharma deal, Merck wagers on strength of lung drug's patents | ||
| Fr | FDA turns back Capricor's Duchenne cell therapy | ||
| 10.07. | Soleno sales of new Prader-Willi drug rise faster than expected | ||
| 10.07. | Moderna COVID vaccine gets full approval for children | ||
| 10.07. | FDA, in policy shift, publishes some drug rejection letters | ||
| 10.07. | AbbVie to pay $700M for trispecific drug from Ichnos Glenmark | ||
| 10.07. | Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding | ||
| 09.07. | Lilly gets FDA OK of modified dosing for Alzheimer's drug | ||
| 09.07. | Merck to buy Verona Pharma and its lung drug in $10B deal | ||
| 09.07. | Gilead signs lenacapavir access deal; Arvinas CEO to step down | ||
| 09.07. | Actithera draws new investors to radiopharma drug pitch |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .